Issue Date: March 20, 2019
Issued by: Center for Drug Evaluation and Research
Topic(s): Clinical – Medical, Pediatric Product Development
Status: Final
Pediatric HIV Infection: Drug Development for Treatment
The purpose of this guidance is to provide general recommendations on the development of antiretroviral (ARV) drug products2 for the treatment of human immunodeficiency virus (HIV) infection in pediatric (birth to younger than 18 years of age) patients. This guidance is intended to help sponsors understand when it is appropriate to initiate pediatric formulation development and to begin pediatric studies.
Download the Guidance Document
